Pioneering AutoRegulation to Facilitate the Development of Next Generation Smart Immunotherapies with an Autonomous Self-Regulating Capability: A Preclinical & Translational Assessment
- Addressing how TCEs are showing great efficacy in clinic but remain toxic hindering broader patient access and community use
- Showcasing NovalGen’s AutoRegulation (AR) platform: safeguarding potency and efficacy while preventing T cell exhaustion through built-in self-regulation
- Advancing the world’s first AR-enabled TCE toward the clinic by end of 2025